410 related articles for article (PubMed ID: 32671454)
1. A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib.
Scapinello G; Riva M; Branca A; Pizzi M; Bonaldi L; Martines A; Manni S; Visentin A; Trentin L; Semenzato G; Gurrieri C; Piazza F
Ann Hematol; 2020 Nov; 99(11):2715-2717. PubMed ID: 32671454
[No Abstract] [Full Text] [Related]
2. Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine.
Scapinello G; Pizzi M; Vio S; Nabergoj M; Visentin A; Martines A; Bonaldi L; Trentin L; Semenzato G; Piazza F
Ann Hematol; 2018 Oct; 97(10):2001-2003. PubMed ID: 29728736
[No Abstract] [Full Text] [Related]
3. Double-hit myeloma with IGH/MYC and IGH/CCND1 translocations.
Ji M; Jang S; Lee JH; Seo EJ
Ann Hematol; 2013 Aug; 92(8):1129-31. PubMed ID: 23307601
[No Abstract] [Full Text] [Related]
4. An aggressive B-cell lymphoma with rearrangements of MYC and CCND1 genes: a rare subtype of double-hit lymphoma.
Durot E; Patey M; Luquet I; Gaillard B; Kolb B; Delmer A
Leuk Lymphoma; 2013 Mar; 54(3):649-52. PubMed ID: 22784333
[No Abstract] [Full Text] [Related]
5. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
Jerkeman M; Eskelund CW; Hutchings M; Räty R; Wader KF; Laurell A; Toldbod H; Pedersen LB; Niemann CU; Dahl C; Kuitunen H; Geisler CH; Grønbæk K; Kolstad A
Lancet Haematol; 2018 Mar; 5(3):e109-e116. PubMed ID: 29396091
[TBL] [Abstract][Full Text] [Related]
6. IgH partner breakpoint sequences provide evidence that AID initiates t(11;14) and t(8;14) chromosomal breaks in mantle cell and Burkitt lymphomas.
Greisman HA; Lu Z; Tsai AG; Greiner TC; Yi HS; Lieber MR
Blood; 2012 Oct; 120(14):2864-7. PubMed ID: 22915650
[TBL] [Abstract][Full Text] [Related]
7. Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.
Srour SA; Lee HJ; Nomie K; Ye H; Chen W; Oriabure O; Romaguera J; Wang ML
Br J Haematol; 2018 May; 181(4):561-564. PubMed ID: 28369820
[No Abstract] [Full Text] [Related]
8. Detection of t(12;14)(p13;q32) in a patient with IGH-CCND1 negative mantle cell lymphoma resembling ultra-high risk chronic lymphocytic leukemia.
Miao Y; Wang R; Fan L; Qiu H; Wu Y; Chen Y; Xu W; Li J
Int J Clin Exp Pathol; 2015; 8(6):7494-8. PubMed ID: 26261659
[TBL] [Abstract][Full Text] [Related]
9. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
[TBL] [Abstract][Full Text] [Related]
10. Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma.
Ito K; Okamoto M; Ando M; Kakumae Y; Okamoto A; Inaguma Y; Tokuda M; Yanada M; Yamada S; Emi N
Leuk Lymphoma; 2015 Apr; 56(4):1123-5. PubMed ID: 24828861
[No Abstract] [Full Text] [Related]
11. A methotrexate-associated lymphoproliferative disorder expressing CD10 and BCL6 with the IGH/CCND1 translocation.
Katsuya H; Kizuka-Sano H; Yokoo M; Kidoguchi K; Yamaguchi K; Nishioka A; Ureshino H; Kubota Y; Ando T; Naito S; Ohshima K; Kimura S
Ann Hematol; 2020 Oct; 99(10):2449-2451. PubMed ID: 32851455
[No Abstract] [Full Text] [Related]
12. t(11;14)-positive mantle cell lymphomas lacking cyclin D1 (CCND1) immunostaining because of a CCND1 mutation or exclusive expression of the CCND1b isoform.
Iaccarino I; Afify L; Aukema SM; Reddemann K; Schütt P; Flür M; Klapper W
Haematologica; 2018 Sep; 103(9):e432-e435. PubMed ID: 29773591
[No Abstract] [Full Text] [Related]
13. Unusual concomitant rearrangements of Cyclin D1 and MYC genes in blastoid variant of mantle cell lymphoma: Case report and review of literature.
Delas A; Sophie D; Brousset P; Laurent C
Pathol Res Pract; 2013 Feb; 209(2):115-9. PubMed ID: 23313364
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.
McCulloch R; Visco C; Eyre TA; Frewin R; Phillips N; Tucker DL; Quaglia FM; McMillan A; Lambert J; Crosbie N; Rule S
Br J Haematol; 2020 May; 189(4):684-688. PubMed ID: 32011729
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
McCulloch R; Lewis D; Crosbie N; Eyre TA; Bolam S; Arasaretnam A; Creasey T; Goradia H; McMillan A; Dawi S; Harrison S; Miles O; Robinson A; Dutton D; Wilson MR; McKay P; Follows G; Phillips N; Patmore R; Lambert J; Bishton M; Osborne W; Johnston R; Kirkwood AA; Rule S
Br J Haematol; 2021 Apr; 193(2):290-298. PubMed ID: 33620106
[TBL] [Abstract][Full Text] [Related]
16. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
Ladetto M; Magni M; Pagliano G; De Marco F; Drandi D; Ricca I; Astolfi M; Matteucci P; Guidetti A; Mantoan B; Bodoni CL; Zanni M; Boccadoro M; Gianni AM; Tarella C
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1270-6. PubMed ID: 17162208
[TBL] [Abstract][Full Text] [Related]
17. MYC amplification on double minute chromosomes in plasma cell leukemia with double IGH/CCND1 fusion genes.
Yamamoto K; Yakushijin K; Ito M; Goto H; Higashime A; Kajimoto K; Hayashi Y; Matsuoka H; Minami H
Cancer Genet; 2020 Apr; 242():35-40. PubMed ID: 32035866
[TBL] [Abstract][Full Text] [Related]
18. Current treatment standards and emerging strategies in mantle cell lymphoma.
Dreyling M; Hiddemann W;
Hematology Am Soc Hematol Educ Program; 2009; ():542-51. PubMed ID: 20008239
[TBL] [Abstract][Full Text] [Related]
19. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
Visco C; Chiappella A; Nassi L; Patti C; Ferrero S; Barbero D; Evangelista A; Spina M; Molinari A; Rigacci L; Tani M; Rocco AD; Pinotti G; Fabbri A; Zambello R; Finotto S; Gotti M; Carella AM; Salvi F; Pileri SA; Ladetto M; Ciccone G; Gaidano G; Ruggeri M; Martelli M; Vitolo U
Lancet Haematol; 2017 Jan; 4(1):e15-e23. PubMed ID: 27927586
[TBL] [Abstract][Full Text] [Related]
20. Composite mantle-cell lymphoma and classical Hodgkin lymphoma.
Hayes SJ; Banerjee SS; Cook Y; Houghton JB; Menasce LP
Histopathology; 2006 Apr; 48(5):621-3. PubMed ID: 16623796
[No Abstract] [Full Text] [Related]
[Next] [New Search]